One progressor cell line, F236, had levels of MEK1 in the WCL and EVs similar to regressors, suggesting that MEK1 expression level is not sufficient to serve as a biomarker of whether a tumour is a regressor or progressor and that other characteristics such as mutational burden or production of immune suppressive molecules need to be taken into account. This evidence concerns the gene MAP2K1 and neoplasm.